HHS highlights breast cancer meds that are covered at no cost to members

The Affordable Care Act requires most insurers and employer plans to cover tamoxifen and raloxifene without co-pays or other out-of-pocket costs for women at high risk for breast cancer, according to the U.S. Department of Health & Human Services. "These are risk-reducing medications which have been shown in randomized, controlled trials to significantly reduce the relative risk for certain types of breast cancer in women who are at an increased risk for this disease. But there have been questions as to whether these medications are considered prevention for the purpose of consumer protections," HHS Secretary Kathleen Sebelius and Congresswoman Debbie Wasserman Schultz (D-Fla.) wrote yesterday in a blog post. HHS has issued guidance to clarify that the reform law has expanded access to the chemo-preventive medications for women whose physicians recommend them. Blog Post

Suggested Articles

In a huge win for hospitals, a federal judge has tossed the Trump administration's rule instituting site-neutral payments.

An estimated 73 million Americans with commercial health insurance face limited choices, according to a new American Medical Association study.

Absent adequate reimbursement for time spent on complex patient care, specialists are finding it harder to sustain their practices.